Thiard News@F4F

@newsen.bsky.social

1 day ago

Lucid Diagnostics Engages with Investors at Upcoming Virtual Healthcare Conference Lucid Diagnostics will be featured in a fireside chat at the Needham Virtual Healthcare Conference, focusing on cancer prevention and diagnostics.

Lucid Diagnostics Engages with Investors at Upcoming Virtual Healthcare Conference #United_States #New_York #healthcare #Lucid_Diagnostics #PAVmed

Thiard News@F4F

@newsen.bsky.social

1 week ago

PAVmed Reflects on 2025 Achievements and Advances in Medical Technology PAVmed Inc. shares significant developments from the past year, enhancing its medical technology portfolio, strategic partnerships, and financial standing. Details on future plans and achievements are discussed.

PAVmed Reflects on 2025 Achievements and Advances in Medical Technology #USA #New_York #Lucid_Diagnostics #PAVmed #Veris_Health

Thiard News@F4F

@newsen.bsky.social

2 weeks ago

Lucid Diagnostics Releases Business Update and 2025 Year-End Financial Results Lucid Diagnostics has announced its business update and financial results for the fourth quarter and full year 2025, showcasing impressive growth and strategic achievements.

Lucid Diagnostics Releases Business Update and 2025 Year-End Financial Results #USA #New_York #Lucid_Diagnostics #EsoGuard #PAVmed

Thiard News@F4F

@newsen.bsky.social

2 months ago

Lucid Diagnostics Secures VA Contract to Enhance EsoGuard® Awareness Among Veterans Lucid Diagnostics has received a significant contract from the U.S. Department of Veterans Affairs to expand access to its EsoGuard® test for esophageal precancer, benefiting millions of veterans nationwide.

Lucid Diagnostics Secures VA Contract to Enhance EsoGuard® Awareness Among Veterans #United_States #New_York #Lucid_Diagnostics #EsoGuard #Veterans_Affairs

Thiard News@F4F

@newsen.bsky.social

4 months ago

Lucid Diagnostics Reveals Breakthrough in Esophageal Precancer Detection with Largest Real-World Study Results Lucid Diagnostics has announced impressive results from a large-scale study on esophageal precancer detection, confirming the effectiveness of their non-invasive testing methods.

Lucid Diagnostics Reveals Breakthrough in Esophageal Precancer Detection with Largest Real-World Study Results #USA #New_York #Lucid_Diagnostics #Esophageal_Cancer #Lucida

Thiard News@F4F

@newsen.bsky.social

4 months ago

Lucid Diagnostics Celebrated as One of the Best Workplaces in 2025 by GenomeWeb Lucid Diagnostics has proudly been recognized as a top workplace in GenomeWeb's 2025 Best Places to Work program, affirming its commitment to an inclusive and innovative work culture.

Lucid Diagnostics Celebrated as One of the Best Workplaces in 2025 by GenomeWeb #United_States #New_York #Cancer_Prevention #Lucid_Diagnostics #GenomeWeb

Thiard News@F4F

@newsen.bsky.social

4 months ago

Lucid Diagnostics Set to Engage Investors at MedTech Forum in NYC Lucid Diagnostics will participate in the upcoming Canaccord Genuity MedTech Forum, emphasizing its cancer prevention endeavors and investor engagements.

Lucid Diagnostics Set to Engage Investors at MedTech Forum in NYC #USA #New_York #Lucid_Diagnostics #EsoGuard #PAVmed

Thiard News@F4F

@newsen.bsky.social

4 months ago

PAVmed's Business Update for Q3 2025 Highlights Strategic Developments PAVmed Inc. shares business updates for Q3 2025, confirming strong financial results and innovative technological advancements in medical technology.

PAVmed's Business Update for Q3 2025 Highlights Strategic Developments #USA #New_York #Lucid_Diagnostics #PAVmed #Veris_Health

Thiard News@F4F

@newsen.bsky.social

4 months ago

Lucid Diagnostics Reports Strong Financials and Business Updates for Q3 2025 In Q3 2025, Lucid Diagnostics processed nearly 3,000 EsoGuard tests, raising $1.2 million in revenue with positive Medicare coverage developments.

Lucid Diagnostics Reports Strong Financials and Business Updates for Q3 2025 #USA #New_York #Lucid_Diagnostics #EsoGuard #PAVmed

Thiard News@F4F

@newsen.bsky.social

5 months ago

Lucid Diagnostics to Engage at the Maxim Growth Summit 2025 in New York Lucid Diagnostics, a leader in cancer prevention, will attend the 2025 Maxim Growth Summit in New York. Key meetings with investors are planned.

Lucid Diagnostics to Engage at the Maxim Growth Summit 2025 in New York #United_States #New_York #Lucid_Diagnostics #PAVmed_Inc #Maxim_Growth

Thiard News@F4F

@newsen.bsky.social

6 months ago

Healthcare Leader John R. Palumbo Joins Lucid Diagnostics Board of Directors Lucid Diagnostics has appointed healthcare veteran John R. Palumbo to its Board of Directors, enhancing its strategic leadership amid growth.

Healthcare Leader John R. Palumbo Joins Lucid Diagnostics Board of Directors #USA #New_York #Cancer_Prevention #Lucid_Diagnostics #John_R._Palumbo

Thiard News@F4F

@newsen.bsky.social

6 months ago

Lucid Diagnostics Completes Public Offering, Boosting Cancer Detection Efforts Lucid Diagnostics Inc. has successfully concluded its public offering of common stock, raising crucial funds for cancer prevention initiatives. Learn more!

Lucid Diagnostics Completes Public Offering, Boosting Cancer Detection Efforts #United_States #New_York #Lucid_Diagnostics #cancer_detection #Public_Offering

Thiard News@F4F

@newsen.bsky.social

7 months ago

Lucid Diagnostics Reveals Plans For New Public Stock Offering to Boost Cancer Detection Efforts Lucid Diagnostics has announced its intention to offer common stock in a public offering to enhance its cancer prevention capabilities. Major underwriters will assist in the process.

Lucid Diagnostics Reveals Plans For New Public Stock Offering to Boost Cancer Detection Efforts #United_States #New_York #Lucid_Diagnostics #Esophageal_Cancer #PAVmed_Inc

Thiard News@F4F

@newsen.bsky.social

7 months ago

Lucid Diagnostics to Host Important Investor Call on September 8, 2025, to Discuss Recent Developments On September 8, 2025, Lucid Diagnostics will conduct an investor call to discuss critical outcomes from a recent advisory meeting regarding their cancer detection technology.

Lucid Diagnostics to Host Important Investor Call on September 8, 2025, to Discuss Recent Developments #United_States #New_York #Lucid_Diagnostics #EsoGuard #PAVmed

Thiard News@F4F

@newsen.bsky.social

7 months ago

PAVmed Updates Investors with Q2 2025 Financial Results and Business Developments PAVmed, a medical technology company, presents its second quarter 2025 financial results and essential business updates, showcasing growth and future strategies.

PAVmed Updates Investors with Q2 2025 Financial Results and Business Developments #United_States #New_York #Lucid_Diagnostics #PAVmed #Veris_Health

Thiard News@F4F

@newsen.bsky.social

7 months ago

Lucid Diagnostics Shares Second Quarter 2025 Financial Results and Business Update Lucid Diagnostics reports its Q2 2025 financial results, highlighting progress in cancer detection and upcoming Medicare coverage meetings.

Lucid Diagnostics Shares Second Quarter 2025 Financial Results and Business Update #United_States #New_York #Lucid_Diagnostics #EsoGuard #PAVmed_Inc.

Thiard News@F4F

@newsen.bsky.social

8 months ago

Lucid Diagnostics Announces Participation in Key Investor Conferences Focusing on Cancer Prevention Lucid Diagnostics is set to engage with investors through upcoming conferences, highlighting its innovative cancer prevention approach and key products.

Lucid Diagnostics Announces Participation in Key Investor Conferences Focusing on Cancer Prevention #USA #New_York #Lucid_Diagnostics #EsoGuard #GERD

Thiard News@F4F

@newsen.bsky.social

8 months ago

PAVmed Secures 180-Day Extension from Nasdaq to Meet Minimum Bid Price Requirement PAVmed Inc. announced it has been granted a 180-day extension by Nasdaq to comply with minimum bid price rules, giving them until January 2026 to meet requirements.

PAVmed Secures 180-Day Extension from Nasdaq to Meet Minimum Bid Price Requirement #United_States #New_York #NASDAQ #Lucid_Diagnostics #PAVmed

Thiard News@F4F

@newsen.bsky.social

8 months ago

MolDX Gathers Experts to Review Medicare Coverage for EsoGuard® Esophageal DNA Test MolDX is set to hold a vital meeting with medical experts on September 4, 2025, to reassess Medicare coverage for Lucid Diagnostics' EsoGuard®, focusing on its implications for early esophageal cancer detection.

MolDX Gathers Experts to Review Medicare Coverage for EsoGuard® Esophageal DNA Test #United_States #New_York #Lucid_Diagnostics #EsoGuard #MolDX

Thiard News@F4F

@newsen.bsky.social

9 months ago

Major California Health System Integrates Advanced Esophageal Cancer Precancer Testing Using Lucid Diagnostics' EsoGuard California's healthcare system partners with Lucid Diagnostics to launch a pioneering esophageal precancer testing program, aiming for early detection and prevention.

Major California Health System Integrates Advanced Esophageal Cancer Precancer Testing Using Lucid Diagnostics' EsoGuard #United_States #California #Lucid_Diagnostics #EsoGuard #Hoag_Hospital

Thiard News@F4F

@newsen.bsky.social

10 months ago

Lucid Diagnostics to Join Russell Indexes—A Milestone for Cancer Detection Innovation Lucid Diagnostics has announced its addition to the Russell 2000 and Russell 3000 Indexes. This significant achievement signals growth in cancer detection innovation and potential investment opportunities.

Lucid Diagnostics to Join Russell Indexes—A Milestone for Cancer Detection Innovation #United_States #New_York #Lucid_Diagnostics #Esophageal_Cancer #PAVmed

Thiard News@F4F

@newsen.bsky.social

10 months ago

PAVmed Reports First Quarter 2025 Financials and Business Progress PAVmed has provided its business update and financial results for Q1 2025, showcasing progress in diagnostics and plans for biopharma expansion.

PAVmed Reports First Quarter 2025 Financials and Business Progress #USA #New_York #Lucid_Diagnostics #PAVmed #Veris_Health

Thiard News@F4F

@newsen.bsky.social

10 months ago

Lucid Diagnostics Reports First Quarter 2025 Progress and Financial Highlights Lucid Diagnostics shares significant financial results and business progress for Q1 2025, highlighting advances in cancer prevention diagnostics and upcoming milestones.

Lucid Diagnostics Reports First Quarter 2025 Progress and Financial Highlights #USA #New_York #Lucid_Diagnostics #EsoGuard #PAVmed

Thiard News@F4F

@newsen.bsky.social

11 months ago

Lucid Diagnostics' EsoGuard Esophageal DNA Test Shows Promise in Detecting Precancerous Condition A recent NCI-sponsored study unravels the potential of Lucid Diagnostics' EsoGuard test to detect esophageal precancer in asymptomatic patients, expanding its use.

Lucid Diagnostics' EsoGuard Esophageal DNA Test Shows Promise in Detecting Precancerous Condition #United_States #New_York #Lucid_Diagnostics #EsoGuard #Barrett's_Esophagus

Thiard News@F4F

@newsen.bsky.social

11 months ago

Lucid Diagnostics Completes Successful Public Offering for Cancer Prevention Initiative Lucid Diagnostics has successfully closed its public stock offering, raising approximately $16.1 million to enhance its medical diagnostics for cancer prevention.

Lucid Diagnostics Completes Successful Public Offering for Cancer Prevention Initiative #United_States #New_York #Lucid_Diagnostics #EsoGuard_Test #PAVmed_Inc.

Thiard News@F4F

@newsen.bsky.social

1 year ago

Lucid Diagnostics Announces Pricing for New Public Stock Offering as Growth Strategy Continues Lucid Diagnostics has set the price for its public stock offering aimed at supporting cancer prevention efforts. This move is seen as a critical step for the company's growth.

Lucid Diagnostics Announces Pricing for New Public Stock Offering as Growth Strategy Continues #United_States #New_York #Lucid_Diagnostics #EsoGuard_Test #PAVmed_Inc

Thiard News@F4F

@newsen.bsky.social

1 year ago

Lucid Diagnostics Unveils Plans for Public Offering to Boost Cancer Prevention Efforts Lucid Diagnostics announces its intention to launch an underwritten public offering for common stock. Proceeds will support cancer prevention.

Lucid Diagnostics Unveils Plans for Public Offering to Boost Cancer Prevention Efforts #USA #New_York #Cancer_Prevention #Lucid_Diagnostics #EsoGuard

Thiard News@F4F

@newsen.bsky.social

1 year ago

Lucid Diagnostics Unveils Innovative Campaign Focused on EsoCheck's Life-Saving Technology for Esophageal Cancer Prevention Lucid Diagnostics has launched a campaign to promote EsoCheck's revolutionary cell collection technology amid Esophageal Cancer Awareness Month, enhancing early detection efforts.

Lucid Diagnostics Unveils Innovative Campaign Focused on EsoCheck's Life-Saving Technology for Esophageal Cancer Prevention #United_States #New_York #Lucid_Diagnostics #Esophageal_Cancer #EsoCheck

Thiard News@F4F

@newsen.bsky.social

1 year ago

Lucid Diagnostics Shares Positive Business Update and 2024 Financial Outcomes Lucid Diagnostics publicly shares a robust business update alongside their fourth-quarter and full-year financial results for 2024. Highlights include revenue growth and strategic partnerships.

Lucid Diagnostics Shares Positive Business Update and 2024 Financial Outcomes #United_States #New_York #Cancer_Prevention #Lucid_Diagnostics #EsoGuard

Thiard News@F4F

@newsen.bsky.social

1 year ago

Updated NCCN Guidelines Now Include Screening for Esophageal Precancer Using Lucid Diagnostics' Innovative Test Lucid Diagnostics announces that the updated NCCN guidelines now recommend esophageal precancer screening using its EsoGuard test, enhancing cancer detection methods.

Updated NCCN Guidelines Now Include Screening for Esophageal Precancer Using Lucid Diagnostics' Innovative Test #USA #New_York #Lucid_Diagnostics #EsoGuard #NCCN_Guidelines